Omeche Idoko-Forrester
Family Medicine · Indian Harbour Beach, FLNPI 1669730503
Payments from drug & device makers
Across 59 payments — averaging $20.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$203
- GSK$164
- Amgen$134
- AbbVie$86
- Lilly USA, LLC$80
- Biohaven Pharmaceutical Holding Company Ltd.$63
- plus $451 from 15 others
What the payments were for
- Food & beverage$1,182100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 12 | $203 |
| GSK | 8 | $164 |
| Amgen(2 entities) | 3 | $134 |
| AbbVie | 5 | $86 |
| Lilly USA, LLC | 5 | $80 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $63 |
| Mylan Specialty L.p. | 2 | $48 |
| Exact Sciences | 2 | $48 |
| AstraZeneca | 3 | $46 |
| Novartis | 2 | $38 |
| Coopersurgical, Inc. | 2 | $34 |
| Pfizer | 2 | $32 |
| Merck | 2 | $32 |
| Coloplast | 1 | $28 |
| Bayer | 1 | $28 |
| Innovation Technologies Inc | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Abbott | 1 | $21 |
| Boehringer Ingelheim | 1 | $20 |
| W. L. Gore & Associates, Inc. | 1 | $17 |
| Electromed, Inc. | 1 | $16 |
How this compares
$1,182 in reported general payments places this provider in the 65th percentile of 7,282 family medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 80 | $98,419 |
| EliquisApixaban | 65 | $70,389 |
| OzempicSemaglutide | 30 | $46,910 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $28,831 |
| JanuviaSitagliptin Phosphate | 17 | $28,599 |
| RybelsusSemaglutide | 28 | $28,054 |
| JardianceEmpagliflozin | 17 | $26,327 |
| XareltoRivaroxaban | 20 | $22,020 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 120 | $2,916 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 72 | $2,089 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $2,061 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 15 | $1,880 |
| Gabapentin | 140 | $1,536 |
| Levothyroxine Sodium | 137 | $1,456 |
| Atorvastatin Calcium | 192 | $1,443 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $80 | $98,41980 claims |
| Novo NordiskOzempic, Rybelsus | $203 | $74,96458 claims |
| PfizerEliquis | $32 | $70,38965 claims |
| GSKTrelegy Ellipta | $164 | $28,83124 claims |
| MerckJanuvia | $32 | $28,59917 claims |
| Boehringer IngelheimJardiance | $20 | $26,32717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Indian Harbour Beach
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.